Details of the Drug Reposition

General Information of This Drug (ID: DMSE3I7)

Drug Name
Gemcitabine   DMSE3I7
Synonyms
Gemcitabine hydrochloride; DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
20 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Urinary bladder neoplasm DIS7HACE N.A. Approved [1]
Splenic marginal zone lymphoma DISCGTZY N.A. Approved [1]
Posterior urethra cancer DIS3DNQW N.A. Approved [1]
Pancreatic adenocarcinoma DISKHX7S N.A. Approved [1]
Ovarian neoplasm DISEAFTY N.A. Approved [1]
Ovarian disorder DISHZX9D N.A. Approved [1]
MALT lymphoma DIS1AVVE N.A. Approved [1]
Leukemia DISNAKFL N.A. Approved [1]
Gallbladder carcinoma DISD6ACL N.A. Approved [1]
Fallopian tube neoplasm DISHMMF2 N.A. Approved [1]
Anterior urethra cancer DISAKHZJ N.A. Approved [1]
Carcinoma DISH9F1N 2A00-2F9Z Approved [1]
Recurrent adult burkitt lymphoma DIS6V60A 2A85.6 Approved [1]
Leiomyosarcoma DIS6COXM 2B58 Approved [1]
Pancreatic tumour DIS3U0LK 2C10 Approved [1]
Cholangiocarcinoma DIS71F6X 2C12.10 Approved [1]
Biliary tract cancer DISBNYQL 2C17 Approved [1]
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Approved [1]
Cervical cancer DISFSHPF 2C77.0 Approved [1]
Urethral cancer DISDWYSE 2C93 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 20 Indications(s)
1 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ovarian cancer DISZJHAP 2C73 Withdrawn [2]
------------------------------------------------------------------------------------
4 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Cancer of unknown primary site DISSA12E N.A. Discontinued in Phase 3 [3]
Ureter cancer DISOUKYP N.A. Discontinued in Phase 3 [4]
Upper tract urothelial carcinoma DISTE2ZH N.A. Discontinued in Phase 3 [5]
Meningitis DISQABAA 1D01 Discontinued in Phase 3 [6]
------------------------------------------------------------------------------------
2 Preclinical Indication(s)
Indication Name Indication ID ICD-11 Status REF
Middle East Respiratory Syndrome (MERS) DIS5VPYU 1D64 Preclinical [7]
Severe acute respiratory syndrome (SARS) DISYW14W 1D65 Preclinical [7]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Colon cancer DISVC52G 2B90.Z Investigative [1]
------------------------------------------------------------------------------------

References

1 Gemcitabine FDA Label
2 Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis
3 A Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous Cell Carcinoma
4 A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).
5 The Study of Nasonex Compared With Placebo for the Relief of Symptoms Associated With Acute Bacterial Sinusitis When Used With Antibiotics (Study P04824AM3)
6 Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
7 Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.